Buffalo Pediatric Associates Llp

CLIA Laboratory Citation Details

2
Total Citations
7
Total Deficiencyies
4
Unique D-Tags
CMS Certification Number 33D0706718
Address 1360 North Forest Road, Suite 101, Williamsville, NY, 14221
City Williamsville
State NY
Zip Code14221
Phone716 639-0744
Lab DirectorROBERT KAPLAN

Citation History (2 surveys)

Survey - March 5, 2024

Survey Type: Standard

Survey Event ID: BUN111

Deficiency Tags: D2007 D2009 D2009 D5217 D5217

Summary:

Summary Statement of Deficiencies D2007 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The samples must be examined or tested with the laboratory's regular patient workload by personnel who routinely perform the testing in the laboratory, using the laboratory's routine methods This STANDARD is not met as evidenced by: Based on review of the College of American Pathologists (CAP) Proficiency Test (PT) records and interview with the testing person (TP), the laboratory failed to perform bacteriology PT for all personnel who perform throat culture patient specimen testing. FINDINGS: 1. CAP bacteriology PT samples were tested by the same TP in the first and second events of 2022 as well as all three events for 2023. The PT samples were not rotated among the other eight TP who routinely performed throat culture patient specimen testing. 2. The TP confirmed the findings on March 4, 2024, at approximately 10:00 A.M. D2009 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The individual testing or examining the samples and the laboratory director must attest to the routine integration of the samples into the patient workload using the laboratory's routine methods. This STANDARD is not met as evidenced by: Based on review of the CAP PT records and interview with the TP, the PT attestation forms confirming that PT samples were tested in the same routine manner as patient specimens were not signed. FINDINGS: 1. CAP PT attestation forms for the first and Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- second events of 2022 as well as all events for 2023 were not signed by the laboratory director (LD) and TP. 2. TP confirmed the findings on March 4, 2024, at approximately 10:00 A.M. It could not be determined if PT samples were tested by TP in the same manner as patient specimens. D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. This STANDARD is not met as evidenced by: Based on lack of twice year verification records and interview with the TP, the laboratory failed to perform and document urine colony count twice year verification interpretation. FINDINGS: 1. There was no documentation of twice year urine colony count verification records for 2023. 2. The TP confirmed the findings on March 5, 2024, at approximately 10:30 A.M. 3. Approximately 101 urine colony count patient samples were tested in calendar year 2023. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 17, 2018

Survey Type: Standard

Survey Event ID: RTR611

Deficiency Tags: D1001 D1001

Summary:

Summary Statement of Deficiencies D1001 CERTIFICATE OF WAIVER TESTS CFR(s): 493.15(e) Laboratories eligible for a certificate of waiver must-- (1) Follow manufacturers' instructions for performing the test; and (2) Meet the requirements in subpart B, Certificate of Waiver, of this part. This STANDARD is not met as evidenced by: Based on surveyor review of the laboratory's Quality Control (QC) waived testing records and an interview with the office manager, the laboratory failed to follow the manufacturer's requirements for quality control and test performance requirements for the Magellan ESA LeadCare II. FINDINGS: 1. The office manager confirmed on 01 /17/2018 at 2:30 PM, that the external controls for the ESA LeadCare II were performed. However, the laboratory tested and reported patient samples for lead screening on the Magellan ESA LeadCare II when level 1 and 2 controls were out of range for the following lots: a. QC lot# 1507 expiration date 01/27/17 Level 1 control was reported as 14.8 and the manufacturer's range was 3.3-9.3. Approximately 43 patients were tested and lead results were reported from 06/28/16 through 09/06/16. b. QC lot # 1609 expiration date 03/06/18 Level 2 control was reported as 26.9 and the manufacturer's range was 27.8-36.0. Approximately 48 patients were tested and lead results were reported from 06/30/17 through 10/02/17. c. the laboratory did not retain the control assay sheets and did not record control results for the following lots: 1604 expiration date 10-26-17; 1603 expiration date 9-3-17; 1504 expiration date 10-23-17 and 1508 expiration date 2-12-17. Approximately 111 patients were tested and lead results were reported from 1/4/16 through 5/31/16. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access